在心力衰竭中通过脏缩调节脉动左心室后负荷,以保存的射出分数来治疗心力衰竭
Karl-Philipp Rommel1,2, Stamatia Pagoulatou3, Karl-Patrik Kresoja1
1Department of Cardiology, Heart Center at University of Leipzig and Leipzig Heart Institute, Germany (K.-P.R., K.-P.K., S.R., A.R.S., M.v.R., H.T., K.F., P.L.).
Circulation. Heart failure
|August 30, 2023
概括
脏缺血改善了动脉硬性和心力衰竭中脉动性心室负荷,并保留了喷射分数 (HFpEF). 这种治疗使关键的血液动力学异常正常化,导致HFpEF患者的症状改善.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血管生理学 血管生理学
背景情况:
- 动脉硬化是心力衰竭中血液动力学功能障碍的一个关键因素,心力衰竭的保护射出分数 (HFpEF).
- 患有HFpEF的患者表现出不利的脉动性左心室负荷.
- 高血压是一种常见的并发症和动脉硬化风险因素.
研究的目的:
- 为了研究脏缩对HFpEF患者脉动性左心室负荷的影响.
- 为了比较HFpEF患者和没有心力衰竭的高血压对照之间的血液动力学参数.
- 评估脏缩对动脉顺应,阻抗和波反射的影响.
主要方法:
- 一组HFpEF患者和高血压对照患者经历了脏缩.
- 用经过验证的动脉树计算机模型来分析非侵入性大动脉流动曲线.
- 左心室血管负荷的关键参数,包括总动脉顺应和大动脉阻抗,在术前和术后确定.
主要成果:
- 与对照组相比,HFpEF患者的动脉顺应性较低,大动脉阻抗较高,波反射增加.
- 脏缺血在两组中显著降低了血压和血压变化.
- 在HFpEF患者中,脏缺血增加了动脉合规性和正常化的波反射模式,伴随着症状的改善.
结论:
- 心力衰竭与保存的射出分数与大动脉硬度增加和不良的脉动性心室负载有关.
- 脏缩有效地使这些血液动力学异常在HFpEF中正常化.
- 这些发现表明脏皮化是通过改善血管功能来管理HFpEF的潜在治疗策略.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16